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Abstract
Background: Finding biomedical named entities is one of the most essential tasks in biomedical text mining.
Recently, deep learning-based approaches have been applied to biomedical named entity recognition (BioNER) and
showed promising results. However, as deep learning approaches need an abundant amount of training data, a lack
of data can hinder performance. BioNER datasets are scarce resources and each dataset covers only a small subset of
entity types. Furthermore, many bio entities are polysemous, which is one of the major obstacles in named entity
recognition.
Results: To address the lack of data and the entity type misclassification problem, we propose CollaboNet which
utilizes a combination of multiple NER models. In CollaboNet, models trained on a different dataset are connected to
each other so that a target model obtains information from other collaborator models to reduce false positives. Every
model is an expert on their target entity type and takes turns serving as a target and a collaborator model during
training time. The experimental results show that CollaboNet can be used to greatly reduce the number of false
positives and misclassified entities including polysemous words. CollaboNet achieved state-of-the-art performance in
terms of precision, recall and F1 score.
Conclusions: We demonstrated the benefits of combining multiple models for BioNER. Our model has successfully
reduced the number of misclassified entities and improved the performance by leveraging multiple datasets
annotated for different entity types. Given the state-of-the-art performance of our model, we believe that CollaboNet
can improve the accuracy of downstream biomedical text mining applications such as bio-entity relation extraction.
Keywords: NER, Deep learning, Named entity recognition, Text mining
Background
The amount of biomedical text continues to increase
rapidly. There were 4.7 million full-text online accessible
articles in PubMed Central [1] in 2017. One of the obsta-
cles in utilizing biomedical text data is that it is too large
for a human to read or even search for needed informa-
tion. This has led to the demand for automated extraction
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of valuable information. Text mining can be used to turn
the time-consuming task into a fully automated job [2–7].
Named Entity Recognition (NER) is the computerized
procedure of recognizing and labeling entities in given
texts. In the biomedical domain, typical entity types
include disease, chemical, gene and protein.
Biomedical named entity recognition (BioNER) is an
essential building block of many downstream text mining
applications such as extracting drug-drug interactions [8]
and disease-treatment relations [9]. BioNER is also used
when building a sophisticated biomedical entity search
tool [10] that enables users to pose complex queries to
search for bio-entities.
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NER in biomedical text mining is focused mainly
on dictionary-, rule-, and machined learning-based
approaches [11–16]. Dictionary based systems have a sim-
ple and intuitive structure but they cannot handle unseen
entities or polysemous words, resulting in low recall
[11, 12]. Moreover, building and maintaining a compre-
hensive and up-to-date dictionary involves a consider-
able amount of manual work. The rule based approach
is more scalable, but it needs hand crafted feature
sets to fit a model to a dataset [13, 14]. These rule
and dictionary-based approaches can achieve high pre-
cision [10] but can produce incorrect predictions when
a new word, which is not in the training data, appears
in a sentence (out-of-vocabulary problem). This out-of-
vocabulary problem occurs frequently especially in the
biomedical domain, as it is common for a new biomed-
ical term, such as a new drug name, to be registered in
this domain.
Recently, studies have demonstrated the effectiveness
of deep learning based methods. Sahu and Anand [17]
demonstrated the efficiency of Recurrent Neural Network
(RNN) for NER in biomedical text. Themodel by Sahu and
Anand is composed of a bidirectional Long Short-Term
Memory Network (BiLSTM) and Conditional Random
Field (CRF). Sahu and Anand [17] also used character
level word embeddings but could not demonstrate their
benefits. Habibi et al. [18] combined the BiLSTM-CRF
model implementation of Lample et al. [19] and the word
embeddings of Pyysalo et al. [20]. Habibi et al. [18] utilized
character level word embeddings to capture characteris-
tics, such as orthographic features, of bio-medical entities
and achieved state-of-the-art performance, demonstrat-
ing the effectiveness of character level word embeddings
in BioNER.
Although these models showed some promising results,
NER is still a very challenging task in the biomedical
domain for the following reasons. First, a limited amount
of training data is available for BioNER tasks. Gold-
standard datasets contain annotations of one or two entity
types. For example, the NCBI corpus [21] includes anno-
tations of diseases but not of other types of entities such as
genes and proteins. On the other hand, the JNLPBA cor-
pus [22] contains annotations of only genes and proteins.
Therefore, the data for each entity type comprises only a
small portion of the total amount of annotated data.
Multi-task learning (MTL) is a method for training a
single model for multiple tasks at the same time. MTL
can leverage different datasets that are collected for dif-
ferent but related tasks [23]. Although extracting genes
is different from extracting chemicals, both tasks require
learning some common features that can help understand
the linguistic expressions of biomedical texts. Crichton
et al. [24] developed an MTL model that was trained
on various source datasets containing annotations of
different subsets of entity types. An MTL model by Wang
et al. [25] achieved performance comparable to that of
the state-of-the-art single task NER models. Inspired by
the previous studies, we propose CollaboNet which uses
the collaboration of multiple models. Unlike the conven-
tional MTL methods which use only a single static model,
CollaboNet is composed of multiple models trained on
different datasets for different tasks. Each model in Col-
laboNet is trained on dataset annotated on a specific
type of entity and becomes an expert on their own
entity type.
Despite the high recall obtained by the MTL based
models, the precision of these models is relatively low.
Since MTL based models are trained on multiple types
of entities and larger training data, they have a broader
coverage of various biomedical entities, which naturally
results in high recall. On the other hand, as theMTLmod-
els are trained on combinations of different entity types,
they tend to have difficulty in differentiating among entity
types, resulting in lower precision.
Another reason NER is difficult in the biomedical
domain is that an entity could be labeled as different entity
types depending on its textual context. In our experi-
ments, we observed that many incorrect predictions were
a result of the polysemy problem, in which a word, for
example, can be used as both a gene and disease name.
Models designed to predict disease entities misiden-
tify some genes as diseases. This misidentification of
entity types increases the false positive rate. For instance,
BiLSTM-CRF based models for disease entities mistak-
enly label the gene name “BRCA1” as a disease entity
because there are disease names such as “BRCA1 abnor-
malities” or “Brca1-deficient” in the training set. Besides,
the training set that annotates “VHL” (Von Hippel-Lindau
disease) as a disease entity confuses the models because
VHL is also used as a gene name, since the mutation of
this gene causes VHL disease.
To solve the false positive problems due to polysemous
words, CollaboNet aggregates the results of collaborator
models, and uses them as an additional input to the tar-
get model. Consider the case of predicting the disease
entity VHL utilizing the outputs of gene and chemical
models. Once a gene model predicts VHL as a gene,
the gene model informs a disease model that VHL is
a gene entity so that the disease model will not pre-
dict VHL as a disease. In CollaboNet, each model is
individually trained on an entity type and then further
trained on the outputs of other models that are trained
on the other entity types. The models in CollaboNet
take turns in being the target and collaborator models
during training. Consequently, each model is an expert
in its own domain and helps improve the accuracy by
leveraging the multi-domain information from the other
models.
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Methods
In the following section, we first discuss a BiLSTM-CRF
model for biomedical named entity recognition. The over-
all structure of the BiLSTM-CRF model is illustrated in
Fig. 1. Next, we introduce the structure of CollaboNet,
which is comprised of a set of BiLSTM-CRF models as
shown in Fig. 2.
Problem Definition
Named entity recognition involves annotating words in a
sentence as named entities. More formally, given an input
sequence S = [w1,w2, ...,wN ], we predict corresponding
labels Y = [y1, y2, ..., yN
]
. We use the BIOES scheme [26]
for representing yt , where B stands for Beginning, I for
Inside, O for Out, E for End, and S for Single.
Embedding layer
Word Embedding (WE)
Word embedding is an effective way of representing
words. As word embeddings capture semantic and syn-
tactic meanings of words, they have been widely used
in various natural language processing tasks including
named entity recognition. The experiment of Habibi et al.
[18] showed that word embeddings trained on biomedi-
cal corpora notably improved the performance of BioNER
models. Pyysalo et al. [20] were the first to suggest training
word embeddings on biomedical corpora from PubMed,
PubMed Central (PMC), and Wikipedia. The results of
Pyysalo et al. [20] and Habibi et al. [18] suggest that using
word embeddings trained on biomedical corpora is essen-
tial for BioNER.We also use the trained word embeddings
provided by Pyysalo et al. [20]. For each word wt in a
sequence S, we denote a word represented by a word
embedding as xt ∈ Rdword where dword is a dimension of
the word embedding.
Character Level Word Embedding (CLWE)
To give our model character level morphological infor-
mation (e.g., ‘-ase’ is common in protein entities), we also
leverage the character level information of each word. We
build character level word embeddings (CLWEs) using a
convolution neural network (CNN), similar to the work of
Santos and Zadrozny [27]. Given a word wt , composed of
M number of characters, we representwt =
{
ct1, ct2, ..., ctM
}
where cti ∈ Rd
char is a randomly initialized character
embedding for each unique character. Note that unlike
the word embeddings trained on separate biomedical cor-
pora, character embeddings are learned from only the
BioNER task. For the CNN, padding of the proper size
((k − 1) /2) according to window size k should be attached
before and after each word. We obtain a window vector
Cti by simply concatenating the character embeddings of
cti with the character embeddings of (k − 1) /2 characters
on both sides:
Cti =
[
cti−(k−1)/2, · · · cti , · · · cti+(k−1)/2
]
∈ Rkdchar (1)
From the window vector Cti , we perform a convolution
operation as follows:
[
xct
]
j = max1≤i≤M
[
WcharCti + bchar
]
j (2)
Fig. 1 Character level word embedding using CNN and an overview of Bidirectional LSTM with Conditional Random Field (BiLSTM-CRF). Single-task
model structure
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Fig. 2 Structure of CollaboNet. Arrows show the flow of information
when target modelMTarget is training. The models in CollaboNet take
turns in being the target model
where Wchar ∈ Rdclwe×kdchar and bchar ∈ Rdclwe denote
a trainable filter and bias, respectively. We obtain the
element-wise maximum values, and the output is a char-
acter level word embedding denoted as xct ∈ Rdclwe . We
concatenate the character level word embedding with
the word embedding trained on biomedical corpora as
xˆt =
[
xt , xct
]
to utilize both representations in our model.
Long Short-TermMemory (LSTM)
A Recurrent Neural Network (RNN) is a neural network
that effectively handles variable-length inputs. RNNs have
proven to be useful in various natural language process-
ing tasks including language modeling, speech recogni-
tion and machine translation [28–30]. Long Short-Term
Memory (LSTM) [31] is one of the most frequently used
variants of recurrent neural networks. Our model uses the
LSTM architecture from Graves et al. [29]. Given the out-
puts of an embedding layer
[
xˆ1, ..., xˆN
]
, the hidden states
of LSTM are calculated as follows:
it = σ
(
Wxixˆt + Whiht−1 + bi
)
(3)
ft = σ
(
Wxf xˆt + Whf ht−1 + bf
)
(4)
ct = ft  ct−1 + it  tanh
(
Wxcxˆt + Whcht−1 + bc
)
(5)
ot = σ
(
Wxoxˆt + Whoht−1 + bo
)
(6)
ht = ot  tanh (ct) (7)
where σ and tanh denote a logistic sigmoid function
and a hyperbolic tangent function, respectively, and  is
an element-wise product. We use a forward LSTM that
extracts the representations of inputs in the forward direc-
tion, and we use a backward LSTM that represents the
inputs in the backward direction.
We concatenate the two states coming from the forward
LSTM and the backward LSTM to form the hidden states
of the bi-directional LSTM (BiLSTM). BiLSTM, proposed
by Schuster and Paliwal [32], was extensively used in var-
ious sequence encoding tasks. We obtain a set of hidden
states hbit =
[
hft , hbt
]
∈ R2dlstm where hft and hbt are hidden
states of forward and backward LSTMs, respectively, at a
time step t.
Bidirectional LSTMwith Conditional Random Field
(BiLSTM-CRF)
While BiLSTM handles long term dependency problems
as well as backward dependency issues, modeling depen-
dencies among adjacent output tags helps improve the
performance of the sequence labeling models [25]. We
applied a Conditional Random Field (CRF) to the output
layer of the BiLSTM to capture these dependencies.
First, we compute the probability of each label given the
sequence S = [w1, ...,wN ] as follows:
zt = Wyhbit + by (8)
p(yt|w1, ...,wN ;) = softmax(zt)
softmax(aj) = exp aj∑
k exp ak
(9)
where Wy ∈ R5×2dlstm and by ∈ R5 are parameters of the
fully connected layer for BIOES tags, and the softmax(·)
function computes the probability of each tag. Based on
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the probability p and the CRF layer, our training objective
to minimize is defined as follows:
LLSTM = −
N∑
t=1
log p(yt|w1, ...,wN ;) (10)
LCRF = −
T∑
t=1
(
Ayt−1,yt + zt,yt
)
(11)
Loss = LLSTM + LCRF (12)
where LLSTM is the cross entropy loss for the label yt ,
and LCRF is the negative sentence-level log likelihood. The
score of a tag is the summation of the transition score
Ayt−1,yt and the emission score from our LSTM zt,yt at time
step t.
At test time, we use Viterbi decoding to find the most
probable sequence given the outputs of the BiLSTM-CRF
model.
CollaboNet
CollaboNet, our novel NER model, is composed of mul-
tiple BiLSTM-CRF models (Fig. 2), and following the
terminology of [25], we call each BiLSTM-CRF model
a single-task model (STM). In CollaboNet, each STM is
trained on a specific dataset and each STM is regarded
as an expert on a particular entity type. These experts
help each other since the knowledge of each expert is
transferred to all the other experts. Training CollaboNet
consists of phases and in each phase, except for the first
preparation phase, only the target STM is trained on a sin-
gle dataset for one epoch while the other STMs are not
trained but only used to generate input for the target STM
which is trained.
More formally, let us denote a set of datasets as D, and
a single-task model as Mnk , which is trained on the k-
th dataset in phase Pn. In the preparation phase
(
P0
)
of
CollaboNet, each STM is trained independently on a cor-
responding dataset until the performance of each model
converges.
Note that an STM in the preparation phase
(
M0k
)
is the
same as a single BiLSTM-CRF model. In the preparation
phase, we assume that each model M0k has obtained the
maximum amount of knowledge about the k-th dataset.
In the subsequent phases Pn, where n ≥ 1, we select
an STM Mn−1d which is an expert on the dataset d. We
refer to the target STM Mn−1d as the target model, and
the remaining STMs as the collaborator models. To train
the target model Mn−1d , we use inputs from the target
dataset d and BiLSTM outputs from collaborator mod-
els Mn−1k , {k|k = d, k ∈ D}. We train each STM on its
dataset for one epoch, and change the target STM Mn−1d
as follows:
Sˆnd = αk1Mn−1k1 ([ Sd; 0] )  · · ·  αkmMn−1km ([ Sd; 0] ),
{ki|ki = d, ki ∈ S}
(13)
pˆ(Yd|Sd) = Mn−1d
(
[ Sd; Sˆnd]
)
(14)
where [ ·; ·] denotes concatenation and  denotes an
aggregation operation such as max pooling or concatena-
tion. We used weighted max pooling for the aggregation
operation. Sd is the input sequences of d-th dataset, and
Mn−1d (·) is output ht , defined by Eq. 7. When aggregat-
ing the results of collaborator models, we multiply each of
the results by a weight αk , which is a trainable parameter.
The results are used to train the model Mn−1d . Using the
outputs obtained by Eq. 14, we trainMn−1d for one epoch,
and it becomes Mnd in the next phase. The CRF layer is
attached to the final output ofMnk . Once we iterate all the
target datasets d ∈ D, the next phase begins.
During the training phase Pn for d, the target STM,
which is composed of the BiLSTM layer and the CRF layer,
and weights αk {k|k = d, k ∈ D} are trained. Parameters
of the other STMs are not trained but the STMs gen-
erate only inferences on dataset d in the training phase
Pn. For example, when the disease dataset is the target
dataset, the BiLSTM of the other STMs produces infer-
ences about the other entity types for the disease dataset.
More specifically, inferences about genes for the disease
datasetMn−1gene([ Sdisease; 0] ) which has rich information on
gene entities, will benefit the disease STM.
Experiments
Datasets
We used 5 datasets (BC2GM [33], BC4CHEMD [34],
BC5CDR [35–38], JNLPBA [22], NCBI [21]), all of which
were collected by Crichton et al [24] (Table 1). Each
of the 5 datasets were constructed from MEDLINE
abstracts, and we used the BIOES notation format for
named entity labels [26]. Each dataset focuses on one of
the three biomedical entity types: disease, chemical, and
gene/protein. We did not use cell-type entity tags from
JNLPBA for the entity types.
All the datasets are comprised of pairs of input sen-
tences and biomedical entity labels for the sentences.
While the JNLPBA dataset has only training and test sets,
the other four datasets contain training, development and
test sets. For JNLPBA, we used part of its training set as
its development set which is the same size as its test set.
Also, we found that the JNLPBA dataset from Crichton
et al. [24] contained sentences that were incorrectly split.
So we preprocessed the original dataset by Kim et al. [22]
with a more accurate sentence separation.
The BC5CDR dataset has the sub-datasets BC5CDR-
chem, BC5CDR-disease and BC5CDR-both, and they
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Table 1 Descriptions of datasets
Datasets Entity type # of sentence # of annotations Data Size
NCBI-Disease (Dogan et al., 2014) Disease 7639 6881 793 abstracts
JNLPBA (Kim et al., 2004) Gene/Proteins 22,562 35,336 2404 abstracts
BC5CDR (Li et al., 2016) Chemicals 14,228 15,935 1500 articles
BC5CDR (Li et al., 2016) Diseases 14,228 12,852 1500 articles
BC4CHEMD (Krallinger et al., 2015a) Chemicals 86,679 84,310 10,000 abstracts
BC2GM (Akhondi et al., 2014) Gene/Proteins 20,510 24,583 20,000 sentences
contain chemical entity types, disease entity types, and
both entity types, respectively. We reported the perfor-
mance on BC5CDR-chem and BC5CDR-disease. We have
a total of six datasets: BC2GM, BC4CHEMD, BC5CDR-
chem, BC5CDR-disease, JNLPBA, and NCBI.
Metric
For the evaluation of the named entity recognition task,
true positives are counted from exact matches between
predicted entity spans and ground truth spans based on
the BIOES notation.
We also designed and applied a simple post-processing
step that corrects invalid BIOES sequences. This simple
step improved precision by about 0.1 to 0.5%, and thus
boosted the F1 score by about 0.04 to 0.3%.
Precision, recall and F1 scores were used to evaluate the
models.
• M = total number of predicted entities in the
sequence.
• N = total number of ground truth entities in the
sequence.
• C = total number of correct entities.
Precision = P = CM ,Recall = R =
C
N ,
F1score = 2PRP + R
(15)
Settings and hyperparameters
We used the 200 dimensional word embedding (WE) by
Pyysalo et al. [20] which was trained on PubMed, PubMed
Central (PMC) andWikipedia text, and it contains about 5
million words. Word2vec [39] was used to train the word
embedding. For character level word embedding (CLWE),
we used window sizes of 3, 5, and 7.
We used AdaGrad optimizer [40] with an initial learn-
ing rate of 0.01 which was exponentially decayed for each
epoch by 0.95. The dimension of the character embed-
ding (dchar) was 30 and dimension of the character level
word embedding (dclwe) was 200*3. We used 300 hidden
units for both forward and backward LSTMs. Weights
for aggregating the results of collaborator models were
uniformly initialized with 1. We applied dropout [41] to
two parts of CollaboNet: output of CLWE (0.5) and output
of BiLSTM (0.3). The mini-batch size for our experiment
was 10.
Most of our hyperparameter settings are similar to those
ofWang et al. [25]. Only a few settings such as the dropout
rates were different from the hyperparameters of Wang.
We tuned these hyperparameters using validation sets.
The preparation phase P0 for 6 datasets takes approx-
imately 900 min, which is the same amount of time it
takes to train 6 single-task models. The rest of the phases
Pn, n ≥ 1 require 3000 min for complete training. If we
exclude BC4CHEMD, the largest dataset, then the train-
ing time for Pn is reduced to 1500 min, which is half the
time required for the remainder phases. Experiments were
conducted on a 10-core CPU (Intel Xeon E5-260 v4 CPU
2.2 GHz) with one graphics processing unit (NVIDIA
Titan Xp). Our code is written in TensorFlow 1.7 (GPU
enabled version) for Python 2.7.
Results
The experimental results of the baseline models and Col-
laboNet are provided in Tables 2 and 3, respectively.
Table 2 shows the results of the single-taskmodels (STMs)
where Table 3 shows the comparison between the exist-
ing state-of-the-art multi-task learningmodel (MTM) and
our CollaboNet.
Since Wang et al. [25] used BC5CDR-both for their
experiments, we reran their models on BC5CDR-chem
and BC5CDR-disease for a fair comparison with other
models. The rerun scores are denoted with asterisks. We
conducted 10 experiments with 10 different random ini-
tializations on our STM. We take arithmetic mean over
the 6 datasets to compare the overall performance of each
model.
Performance of single-task models
Table 2 shows the results of the STMs of Habibi et al. [18]
and Wang et al. [25] (baseline STMs), and our STM on
the 6 datasets. While the baseline STMs applied BiLSTM
for the Character Level Word Embedding (CLWE) layer
[18, 25], our STM used Convolution Neural Network
(CNN) for the CLWE layer.
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Table 2 Performances of single-task models
Model Habibi et al. (2017) STM Wang et al. (2018) STM Our STM
Dataset Precision Recall F1 Score Precision Recall F1 Score Precision Recall F1 Score
NCBI-disease 85.31 83.58 84.44 84.95 82.92 83.92 83.95 85.45 84.69 (±0.54)
JNLPBA 74.83 79.82 77.25 69.60 74.95 72.17 72.51 82.98 77.39 (±0.24)
BC5CDR-chem 92.57 88.77 90.63 *93.05 *86.87 *89.85 94.02 91.50 92.74 (±0.47)
BC5CDR-disease 84.19 82.79 83.49 *84.09 *81.32 *82.68 82.98 82.25 82.61 (±0.25)
BC4CHEMD 87.83 85.45 86.62 90.53 87.04 88.75 90.50 85.96 88.19 (±0.23)
BC2GM 77.50 78.13 77.82 81.11 78.91 80.00 79.70 77.47 78.56 (±0.38)
Macro Average 83.71 83.09 83.38 83.89 82.00 82.90 83.94 84.27 84.03
Our STM achieved the best performance on 3 datasets among 6. Scores in the asterisked (*) cells are obtained in the experiments that we conducted; these scores are not
reported in the original papers. The best scores from these experiments are in bold
On average, our STM outperforms the baseline STMs
in terms of precision, recall and F1 score. Although, Sahu
and Anand [17] tried to improve the performance of NER
models with CNN based CLWE layer, they have failed to
do so. In our experiments, however, our STMoutperforms
other baseline STMs, demonstrating the effectiveness of
STM with CNN based CLWE layer.
Performance of CollaboNet
Comparing Tables 2 and 3, CollaboNet achieves higher
precision and F1 score than most STM models on all
datasets. On average, CollaboNet has improved both
precision and recall. CollaboNet also outperforms the
multi-task model (MTM) from Wang et al. [25] on 4
out of 6 datasets (Table 3). While multi-task learning
has improved performance in previous studies [25], using
CollaboNet, which consists of expert models trained for
each entity type, could further improve biomedical named
entity recognition performance.
Discussion
Compared to baseline models, CollaboNet achieves
higher performance on macro average (Tables 2 and 3).
The increase in precision is supportive when considering
the practical use of the bioNER systems. In a number of
biomedical text mining systems, important information
tends to be repeated in a large size text corpus. Therefore,
missing a few entities may not hinder the performance of
an entire system, as this can be compensated elsewhere.
However, incorrect information and the propagation of
errors can effect the entire system.
In Table 4, we report the error types of our STM and
CollaboNet. We define bio-entity error as recognizing dif-
ferent types of biomedical entities as target entity types.
For instance, recognizing ‘VHL’ as a gene when it was
used as a disease in a sentence is a bio-entity error. Note
that a bio-entity error could occur when an entity is a
polysemous word (e.g. VHL), or comprised of multiple
words (e.g. BRCA1 deficient), and thus correcting bio-
entity errors requires contextual information or supervi-
sion of other entity type models. The error analysis was
conducted on 4334 errors of our STM and 3966 errors
of CollaboNet on 5 datasets (BC2GM, BC5CDR-chem,
BC5CDR-disease, JNLPBA, NCBI). Error analysis was
conducted on models which showed best performance in
our experiments.
The error analysis of our STM, which is a single
BiLSTM-CRF model, shows that the majority of errors
Table 3 Performance of CollaboNet and the Multi-Task Model by Wang et al. [25]
Model Wang et al. (2018) MTM CollaboNet
Dataset Precision Recall F1 Score Precision Recall F1 Score
NCBI-disease 85.86 86.42 86.14 85.48 87.27 86.36 (±0.54)
JNLPBA 70.91 76.34 73.52 74.43 83.22 78.58
BC5CDR-chem *93.09 *89.56 *91.29 94.26 92.38 93.31
BC5CDR-disease *83.73 *82.93 *83.33 85.61 82.61 84.08
BC4CHEMD 91.30 87.53 89.37 90.78 87.01 88.85
BC2GM 82.10 79.42 80.74 80.49 78.99 79.73
Macro Average 84.50 83.70 84.07 85.18 85.25 85.15
Scores in the asterisked (*) cells are obtained in the experiments that we conducted; these scores are not reported in the original papers. The best scores from these
experiments are in bold
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Table 4 The number of bio-entity type errors, the total number of errors, and the ratio of bio-entity errors to the total numbers of
errors for each model prediction
Our STM CollaboNet
Dataset Bio Entity Total Ratio of Bio Entity Bio Entity Total Ratio of Bio Entity Difference
NCBI-disease 54 167 32.3% 38 131 29.0% -3.3%
JNLPBA 749 1520 49.3% 227 1437 15.8% -33.5%
BC5CDR-chem 142 503 28.2% 122 505 24.2% -4.1%
BC5CDR-disease 199 867 23.0% 131 728 18.0% -5.0%
BC2GM 189 1277 14.8% 218 1165 18.7% 3.9%
Negative values at the difference tab indicate that CollaboNet reduced the number of false positives, especially false biomedical entities
are classified as bio-entity errors which comprise up to
49.3% of the total errors in JNLPBA. According to the
error analysis of our STMmodel, bio-entity errors consti-
tute 1333 errors out of 4334 errors, comprising 30.8% of
all the errors. Although bio-entity error was not the most
common error type, the importance of bio-entity error
is much greater that of other errors such as span error
which was the most common error type, constituting 38%
of incorrect errors. While most span errors can be eas-
ily fixed by non-experts, bio-entity errors are difficult to
detect and fix, even for biomedical researchers. Also, for
biomedical text mining tasks such as drug-drug interac-
tion (DDI) extraction, span errors of an NER system have
a minor effect on DDI results but bio-entity errors could
lead to completely different results.
The performance improvement of CollaboNet over
STM may not seem significant when considering the
increased complexity of CollaboNet’s structure. We found
by error analysis that CollaboNet had an increased num-
ber of span errors. As our metric is based on the exact
match evaluation, consistent annotation of the ground
truth dataset is important for reducing span errors which
are caused by modifiers. For instance, in the phrase “acute
adult renal failure,” “adult renal failure” may be labeled as
an entity in some datasets. In this case, predicting “acute
adult renal failure” or “renal failure” as an entity will be
counted as a false negative and a false positive. On the
other hand, some other datasets may include the modifier
“acute” in an entity, considering “acute adult renal fail-
ure” as the only true prediction. Therefore, unlike STM,
CollaboNet uses various datasets that have been anno-
tated differently. Even though CollaboNet outperforms
STM, its results may be lower due to this inconsistency in
annotation.
In CollaboNet, each expert model is trained on a single
entity type dataset, and their training inputs are a con-
catenation of word embeddings and outputs of the other
expert models. We expect that the other expert models
will transfer knowledge on their respective entity to the
target model, and thus improve the bio-entity type error
problem by collaboration. As Table 4 shows, CollaboNet
performs better than our STM in detecting polysemy and
other entity types. Among 3966 errors from CollaboNet,
736 errors are bio-entity errors, comprising 18.6% of all
the errors.
Case study
We sampled the predictions of CollaboNet and those of
our STM (single-task model) to further understand the
strengths of CollaboNet in Table 5.
The first example from chemical dataset in Table 5
shows our expected result from CollaboNet. Our STM
annotates antilymphocyte globulin as a chemical entity.
However, it is clear that the entity is not a chemical but a
type of globulin which is a protein. The second example
sentence from the chemical dataset is about anACE / ARB
entity. Again, our STMmisidentifies the entity as a chem-
ical entity. On the other hand, in CollaboNet, the target
model (chemical model) obtains knowledge from one of
the collaborator models (the gene/protein model) to avoid
mistakenly recognizing the entity as a chemical entity.
As globulin or ACE entities appear in the gene/protein
dataset, the chemical model obtains information from the
gene/protein model.
In the disease dataset, the first example shows a multi-
word entity in parentheses. As a gene model can pass
syntactic and semantic information about a word e.g.,
mutated and its surrounding words to a disease model,
CollaboNet can abstain from predicting A-T, mutated as
the disease entity, which our STMmodel failed to do. The
second example in the disease dataset is on cardiac tro-
ponin T. Since cardiac + noun in biomedical text can be
easily considered as a disease name, our STM misidenti-
fied this word as a disease entity. However, with the help
of a gene model, CollaboNet did not mark it as a disease
entity.
The gene/protein entity type further demonstrates
the effectiveness of CollaboNet in reducing bio-entity
type errors. Two example sentences contain abbrevi-
ations, which are one of the distinct characteristics
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Table 5 Case study
Chemical dataset
Our STM No prophylaxis with antilymphocyte globulin was used - globulin : Protein
CollaboNet No prophylaxis with antilymphocyte globulin was used
Ground Truth No prophylaxis with antilymphocyte globulin was used
Our STM elderly patients using ACE / ARB in combination with potassium ACE : Gene/Protein
CollaboNet elderly patients using ACE / ARB in combination with potassium
Ground Truth elderly patients using ACE / ARB in combination with potassium
Disease Dataset
Our STM The ATM (A-T, mutated) gene on human chromosome 11q22. A-T, mutated : Gene
CollaboNet The ATM (A-T, mutated) gene on human chromosome 11q22.
Ground Truth The ATM (A-T, mutated) gene on human chromosome 11q22.
Our STM to bind to the human cardiac troponin T (cTNT) pre-messenger RNA cTNT : Gene/Protein
CollaboNet to bind to the human cardiac troponin T (cTNT) pre-messenger RNA
Ground Truth to bind to the human cardiac troponin T (cTNT) pre-messenger RNA
Gene / Protein Dataset
Our STM which is inhibited by the cytotoxin leptomycin B (LMB), and also by its interaction LMB : Chemical, Drug
CollaboNet which is inhibited by the cytotoxin leptomycin B (LMB), and also by its interaction
Ground Truth which is inhibited by the cytotoxin leptomycin B (LMB), and also by its interaction
Our STM Classic Hodgkin disease (cHD) is derived from B cells with high loads of mutations. cHD : Disease
CollaboNet Classic Hodgkin disease (cHD) is derived from B cells with high loads of mutations
Ground Truth Classic Hodgkin disease (cHD) is derived from B cells with high loads of mutations
This table contains sentences that were incorrectly predicted by of our STM but were correctly predicted by CollaboNet. The predicted labels or the ground truth labels are
underlined
of gene entities. LMB and cHD are incorrectly pre-
dicted as gene/protein entities by our STM, since lots
of gene/protein entities are abbreviations. However, the
target model (gene/protein model) in CollaboNet can
obtain information on leptomycin and disease from the
chemical and disease models, respectively. With the help
of information from collaborator models, CollaboNet
can effectively increase the precision of other entity
type models.
In addition, we found some labels in the ground truth
set, which we believe are incorrect. Tsai et al. [15] also
reported that the inconsistent annotations in the JNLPBA
corpus limit the NER system. We report our findings in
Table 6.
Table 6 Case study
Gene / Protein Dataset
CollaboNet Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in THP-1 cells.
Ground Truth Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in THP-1 cells
CollaboNet The translesion DNA polymerase zeta plays a major role in lg and bcl-6 somatic hypermutation.
Ground Truth The translesion DNA polymerase zeta plays a major role in lg and bcl-6 somatic hypermutation.
Chemical Dataset
CollaboNet recently identified Delta22-isomer of beta-muricholate contribute for 5.4%
Ground Truth recently identified Delta22-isomer of beta-muricholate contribute for 5.4%
CollaboNet Hexabrix and polyvidone are considered the best contrast media for hysterosalpingography.
Ground Truth Hexabrix and polyvidone are considered the best contrast media for hysterosalpingography.
This table shows the questionable answers from the ground truth datasets. Our model achieves better performance in detecting entities in these example sentences. The
predicted labels or the ground truth labels are underlined
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In the first row of Table 6, the gene/protein entity
osteopontin was not marked in the ground truth labels,
whereas our network correctly predicted it as a gene
entity. The second row also displays questionable results
of the ground truth labels. Although lg and bcl-6, which
are abbreviations of Immunoglobulin and B-cell lym-
phoma 6, where not labeled in the ground truth labels, our
model detected them as a gene / protein entity. The exam-
ple sentences of gene/protein annotations in Table 6 were
reviewed by several domain experts and medical doctors.
As shown in the third row, beta-muricholate is a chemical
entity but it was not annotated in the ground truth labels.
However, the last row shows another type of annotation
error. Contrast media is a general term for a medium used
in medical imaging and since is not a proper noun, it is not
a named entity.
These examples shows the presence of incorrect ground
truth labels, which can harm the performance of bioNER
models. However, we believe that these missed or
misidentified ground truth labels can be corrected by our
system.
Future works
For future work, we plan to cover more target entity
types and use more datasets. For example, CRAFT [42],
LINNAEUS [43] and Variome [44] are manually anno-
tated datasets and are valuable resources that can be used
for expanding our model. Second, we plan to apply Col-
laboNet to downstream biomedical text mining systems.
For example, entity search engines such as BEST [10]
could be improved by using more accurate NER models.
Conclusion
In this paper, we introduced CollaboNet, which con-
sists of multiple BiLSTM-CRF models, for biomedical
named entity recognition. While existing models were
only able to handle datasets with a single entity type,
CollaboNet leverages multiple datasets and achieves the
highest F1 scores. Unlike recently proposed multi-task
models, CollaboNet is built upon multiple single-task
NER models (STMs) that send information to each other
for more accurate predictions. In addition to the perfor-
mance improvement over multi-task models, CollaboNet
differentiates between biomedical entities that are pol-
ysemous or have similar orthographic features. As a
result, our model achieved state-of-the-art performance
on four bioNER datasets in terms of F1 score, precision
and recall. Although our model requires a large amount
of memory and time, which existing multi-task models
require as well, the simple structure of CollaboNet allows
researchers to build another expert model for different
entity types in CollaboNet. As CollaboNet obtains higher
precision than other models, we plan to apply CollaboNet
in a biomedical text mining system.
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